E2 ModerateModerate confidencePEM unclearCase-ControlPeer-reviewedMachine draft
Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells.
Mihaylova, Ivana, DeRuyter, Marcel, Rummens, Jean-Luc et al. · Neuro endocrinology letters · 2007
Quick Summary
This study looked at immune cell activation in people with ME/CFS by measuring a protein called CD69 on the surface of immune cells. Researchers found that ME/CFS patients had significantly lower levels of this activation marker on their T cells and natural killer cells compared to healthy people, even though the total number of immune cells was normal. This suggests that immune cells in ME/CFS may have trouble becoming activated properly in response to challenges.
Why It Matters
This study provides objective immunological evidence that ME/CFS involves a specific defect in how immune cells activate, rather than simply having abnormal cell numbers. The high diagnostic accuracy (89% ROC AUC) suggests CD69 expression could potentially serve as a biological marker to help identify and study the disease.
Observed Findings
- CD69 expression on T cells (CD3+), helper T cells (CD3+CD4+), and cytotoxic T cells (CD3+CD8+) was significantly lower in CFS patients than healthy controls.
- CD69 expression on natural killer cells (CD45+CD56+) was significantly decreased in CFS patients.
- No differences were found between CFS patients and controls in total leukocyte counts or absolute/relative numbers of lymphocyte subsets (CD3, CD4, CD8, CD19).
- CD69 measurement achieved approximately 89% accuracy (ROC AUC) in distinguishing CFS patients from healthy controls.
Inferred Conclusions
- CFS patients have a selective defect in T cell and NK cell activation despite normal cell counts, indicating a functional rather than quantitative immune abnormality.
- The PKC signaling pathway may be impaired in early immune cell activation in CFS, since CD69 induction depends on PKC activation.
Remaining Questions
- Does this CD69 defect persist over time or fluctuate with disease severity in individual patients?
- Does the CD69 abnormality correlate with specific ME/CFS symptoms or clinical severity?
- Could this immune activation defect be reversed or improved through treatment, and would correction improve symptoms?
- Is the PKC pathway dysfunction directly responsible for the CD69 defect, or are other upstream mechanisms involved?
What This Study Does Not Prove
This study does not prove that the CD69 defect causes ME/CFS symptoms or is the primary driver of disease—it only shows an association. The study cannot determine whether this immune abnormality is a cause, consequence, or contributing factor to the condition. Additionally, measuring activation in response to laboratory stimulation may not fully reflect how immune cells behave in the body during actual illness.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:Small SampleExploratory Only
Metadata
- PMID
- 17693977
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →